Welcome to our dedicated page for Madrigal Pharmac news (Ticker: MDGL), a resource for investors and traders seeking the latest updates and insights on Madrigal Pharmac stock.
Madrigal Pharmaceuticals, Inc. (MDGL) is a clinical-stage biopharmaceutical company pioneering treatments for metabolic dysfunction-associated steatohepatitis (MASH), including its FDA-approved therapy Rezdiffra. This page provides investors and healthcare professionals with timely updates on corporate milestones, clinical research, and regulatory developments.
Access the latest press releases, earnings reports, and scientific announcements in one centralized location. Key updates include Rezdiffra's commercialization progress, new clinical data analyses, and strategic partnerships advancing MASH treatment innovation. Our curated news collection ensures you stay informed about material events without speculative commentary.
Regular updates cover regulatory submissions, trial expansions, financial disclosures, and patient access initiatives. Content is rigorously verified to provide accurate, actionable information for investment and therapeutic decision-making. Bookmark this page to monitor Madrigal's progress in addressing critical unmet needs in liver disease therapeutics.
Madrigal Pharmaceuticals (MDGL) shared updates on its progress and reported Q2 2022 financial results. The company is advancing its Phase 3 MAESTRO-NASH biopsy study, with topline data expected in Q4 2022. Resmetirom, an oral medication targeting NASH, shows promise, supported by positive safety data. As of June 30, 2022, Madrigal reported $211.8 million in cash and equivalents, down from $270.3 million at year-end 2021, driven by operational cash use of $107.3 million. Operating expenses rose to $70.3 million, attributed to increased research activities and headcount.
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported promising results from the Phase 3 MAESTRO-NAFLD-1 study of resmetirom at the EASL 2022. The double-blind trial demonstrated that resmetirom was safe, well-tolerated, and led to significant reductions in liver fat, fibrosis measures, and liver enzymes. In patients with compensated NASH cirrhosis, resmetirom reduced liver volume by ~20%, along with lowering LDL-C and other harmful lipids. The company plans to submit a new drug application based on these findings.
Madrigal Pharmaceuticals announced its support for the fifth International NASH Day on June 9, 2022, highlighting its ongoing commitment to enhancing education and care for patients with non-alcoholic steatohepatitis (NASH). The campaign, led by the Global Liver Institute, aims to raise awareness about the liver disease. Madrigal's initiatives include partnerships with community organizations, unrestricted grants to various liver health programs, and the launch of the NASH Explored campaign for healthcare providers, aimed at disseminating vital information regarding NASH.
Madrigal Pharmaceuticals (NASDAQ: MDGL) has announced its participation in three upcoming investor conferences focused on healthcare. The events include the Jefferies Global Healthcare Conference on June 9, 2022, the Goldman Sachs Annual Global Healthcare Conference on June 14, 2022, and the JMP Securities Life Sciences Conference on June 15, 2022. Presentations will be available via webcast and can be re-watched on the company's website. Madrigal is developing treatments for non-alcoholic steatohepatitis (NASH), with its leading candidate, resmetirom, currently in Phase 3 trials.
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced its participation in two investor conferences on May 24, 2022. The company will host a fireside chat at the H.C. Wainwright Global Life Sciences Conference at 7:00 AM ET, followed by another at the UBS Global Healthcare Conference at 8:30 AM ET. Both presentations will be available via webcast and archived for later replay on the Madrigal website. The company focuses on developing novel therapeutics for non-alcoholic steatohepatitis (NASH), with its lead candidate resmetirom under evaluation in Phase 3 studies.
Madrigal Pharmaceuticals (NASDAQ: MDGL) announced that four abstracts, including a late-breaker on the MAESTRO-NAFLD-1 study, were accepted for oral presentation at the EASL International Liver Congress. The Phase 3 study reinforced resmetirom's safety and efficacy for treating non-cirrhotic NASH. The company anticipates disclosing topline data from the MAESTRO-NASH by Q4 and plans to file for accelerated approval next year. Additionally, Madrigal secured a $250 million term loan facility to support its clinical development and potential U.S. launch of resmetirom.
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) will announce its Q1 2022 financial results on May 9, 2022, at 6:30 am ET. The announcement will include updates on their clinical programs and further results from the Phase 3 MAESTRO-NAFLD-1 study. Following the press release, a conference call is scheduled for the same day at 8:00 am ET. Investors can access the live webcast on Madrigal's website, where an archived version will be available post-event. Madrigal focuses on novel therapies for non-alcoholic steatohepatitis (NASH), with its lead candidate, resmetirom, in Phase 3 trials.
Madrigal Pharmaceuticals (NASDAQ: MDGL) announced its participation in the 32nd Annual Oppenheimer Healthcare Conference on March 15, 2022, at 8:00 AM ET. The management team will engage in a fireside chat, which will be webcast live. An archived recording will be available post-event on their website. Madrigal focuses on innovative therapeutics for non-alcoholic steatohepatitis (NASH) and leads with resmetirom, currently in Phase 3 studies.
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported significant advancements in its clinical development for non-alcoholic steatohepatitis (NASH) in a recent press release. Key highlights include achieving primary endpoints in the MAESTRO-NAFLD-1 safety study, indicating that resmetirom is safe and effective in reducing liver fat and atherogenic lipids. Financially, the company reported cash reserves of $270.3 million, down from $284.1 million year-over-year, with operating expenses increasing to $242.5 million. The leadership team has been bolstered with new roles to enhance operational capacity.
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced positive topline results from the Phase 3 MAESTRO-NAFLD-1 study of resmetirom, a treatment for non-alcoholic steatohepatitis (NASH). The 52-week double-blind study with 969 patients demonstrated safety and tolerability at doses of 80 mg and 100 mg. Significant reductions in liver fat and atherogenic lipids were achieved, with nearly half of the 100 mg group experiencing a 50% reduction in liver fat. The company plans to share more data from this trial, reinforcing its regulatory strategy for NASH treatment.
FAQ
What is the current stock price of Madrigal Pharmac (MDGL)?
What is the market cap of Madrigal Pharmac (MDGL)?
